In the BioHarmony Drug Report Database

"Preview" Icon

Azacitidine

Azacitidine, Onureg, Vidaza (azacitidine) is a small molecule pharmaceutical. Azacitidine was first approved as Azacitidine on 2004-05-19. It is used to treat myelomonocytic leukemia chronic, refractory anemia, and sideroblastic anemia in the USA. It has been approved in Europe to treat myelodysplastic syndromes, myeloid leukemia acute, and myelomonocytic leukemia chronic. Vidaza’s patent is valid until 2030-06-03 (FDA).

 

Trade Name

 

Onureg, Vidaza
 

Common Name

 

azacitidine
 

ChEMBL ID

 

CHEMBL1489
 

Indication

 

myelodysplastic syndromes, myeloid leukemia acute, myelomonocytic leukemia chronic, refractory anemia, sideroblastic anemia
 

Drug Class

 

H2-receptor antagonists (cimetidine type)

Image (chem structure or protein)

Azacitidine structure rendering